Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting
FLEX Study Highlights Clinical Utility of MammaPrint® and BluePrint® Read More
FLEX Study Highlights Clinical Utility of MammaPrint® and BluePrint® Read More
FLEX Study reaches milestone of 20,000 enrolled patients, providing Read More
Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among Read More
Poster presentation to highlight new data on MammaPrint® and Read More
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – February 11, Read More
Year-to-Date Achievements Demonstrate Significant Signs of Growth Across All Read More
Gene expression analysis reveals MammaPrint® as the only commercially Read More
New data reinforces findings from MINDACT supporting MammaPrint® in Read More
A secondary analysis of the randomized controlled trial, IDEAL, Read More
New data reinforces MammaPrint® and BluePrint® tests’ expanding clinical Read More